FIRST PHARMACOGENOMIC ANALYSIS USING WHOLE EXOME SEQUENCING TO IDENTIFY NOVEL GENETIC DETERMINANTS OF CLOPIDOGREL RESPONSE VARIABILITY: RESULTS OF THE GENOTYPE INFORMATION AND FUNCTIONAL TESTING (GIFT) EXOME STUDY

Matthew J. Price; Andrew R. Carson; Sarah S. Murray; Tierney Phillips; Lee Janel; Rebecca Tisch; Eric Topol; Samuel Levy

Journal ArticleOPEN ACCESS

FIRST PHARMACOGENOMIC ANALYSIS USING WHOLE EXOME SEQUENCING TO IDENTIFY NOVEL GENETIC DETERMINANTS OF CLOPIDOGREL RESPONSE VARIABILITY: RESULTS OF THE GENOTYPE INFORMATION AND FUNCTIONAL TESTING (GIFT) EXOME STUDY

Price M
Carson A
Murray S
et al.

Journal of the American College of Cardiology (2012) 59(13) E9

DOI: 10.1016/s0735-1097(12)60010-2

N/ACitations

15Readers

Abstract

Although on-treatment reactivity (OTR) while receiving clopidogrel is strongly associated with CYP2C19 genotype, the majority of the hereditability in clopidogrel response variability remains unexplained, supporting the contention that other important genetic determinants have yet to be identified.

Cite

CITATION STYLE

APA

Price, M. J., Carson, A. R., Murray, S. S., Phillips, T., Janel, L., Tisch, R., … Levy, S. (2012). FIRST PHARMACOGENOMIC ANALYSIS USING WHOLE EXOME SEQUENCING TO IDENTIFY NOVEL GENETIC DETERMINANTS OF CLOPIDOGREL RESPONSE VARIABILITY: RESULTS OF THE GENOTYPE INFORMATION AND FUNCTIONAL TESTING (GIFT) EXOME STUDY. Journal of the American College of Cardiology, 59(13), E9. https://doi.org/10.1016/s0735-1097(12)60010-2

FIRST PHARMACOGENOMIC ANALYSIS USING WHOLE EXOME SEQUENCING TO IDENTIFY NOVEL GENETIC DETERMINANTS OF CLOPIDOGREL RESPONSE VARIABILITY: RESULTS OF THE GENOTYPE INFORMATION AND FUNCTIONAL TESTING (GIFT) EXOME STUDY

Abstract

Cite

Register to see more suggestions